English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 44 Help

Selected(0)Clear Items/Page:    Sort:
Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy Journal article
Yang ZhanBo, Chu BiZhu, Tu Yao, Li LuLu, Chen DaWei, Huang ShouHui, Huang WenJun, Fan WeiWen, Li QinYuan, Zhang CunLong, Yuan ZiGao, Huang Jumin, Leung Elaine Lai Han, Jiang Yuyang. Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy[J]. Pharmacological Research, 2024, 206, 107271.
Authors:  Yang ZhanBo;  Chu BiZhu;  Tu Yao;  Li LuLu;  Chen DaWei; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:9.1/9.0 | Submit date：2024/06/17
Dnmt  Hdac  Rig-i/mda5-mavs  Anti-pd-l1 Therapy  Tumor Immune Microenvironment  
Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer Journal article
Zhang YiZhong, Lai HuanLing, Huang Chen, Jiang ZeBo, Yan HaoXin, Wang XuanRun, Xie Chun, Huang JuMin, Ren WenKang, Li JiaXin, Zhai ZhiRan, Yao XiaoJun, Wu QiBiao, Leung Elaine Lai Han. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer[J]. Phytomedicine, 2024, 128, 155431.
Authors:  Zhang YiZhong;  Lai HuanLing;  Huang Chen;  Jiang ZeBo;  Yan HaoXin; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:6.7/6.2 | Submit date：2024/05/16
Er Stress  Jnk  Nfat2  Nsclc  Pd-l1  Tanshinone Iia  
ADCY4 promotes brain metastasis in small cell lung cancer and is associated with energy metabolism Journal article
Sun, Yidan, Chen, Yixun, Zhang, Xin, Yi, Dan, Kong, Fanming, Zhao, Linlin, Liao, Dongying, Chen, Lei, Ma, Qianqian, Wang, Ziheng. ADCY4 promotes brain metastasis in small cell lung cancer and is associated with energy metabolism[J]. Heliyon, 2024, 10(7), e28162.
Authors:  Sun, Yidan;  Chen, Yixun;  Zhang, Xin;  Yi, Dan;  Kong, Fanming; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.4/3.9 | Submit date：2024/05/02
Adcy4  Anti-pd1  Bms  Mfuzz  Sclc  Wgcna  
Characteristics of clinical trials of new oncology drugs approved in China Journal article
Yang, Jing, Yang, Ji, Hu, Yuan Jia. Characteristics of clinical trials of new oncology drugs approved in China[J]. Cancer, 2024, 130(5), 671-682.
Authors:  Yang, Jing;  Yang, Ji;  Hu, Yuan Jia
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/05/16
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors  
Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products Other
2024-01-01
Authors:  ZHANG, Lele;  LU, Jinjian
Favorite | TC[WOS]:4 TC[Scopus]:4 | Submit date：2024/02/22
Combination Strategies  Immunotherapy  Natural Products  Pd-1/pd-l1  Unresectable Hepatocellular Carcinoma  
Review immune response of targeting CD39 in cancer Journal article
Yao Liu, Zhongliang Li, Xiaoguang Zhao, Jing Xiao, Jiacheng Bi, Xian-Yang Li, Guokai Chen, Ligong Lu. Review immune response of targeting CD39 in cancer[J]. Biomarker Research, 2023, 11(1).
Authors:  Yao Liu;  Zhongliang Li;  Xiaoguang Zhao;  Jing Xiao;  Jiacheng Bi; et al.
Favorite | TC[WOS]:14 TC[Scopus]:14  IF:9.5/9.4 | Submit date：2023/08/03
Adenosine Pathway  Cd39  Immune Checkpoint Blockade (Icb)  Pd-1  
Characteristics of clinical trials of new oncology drugs approved in China Review article
2023
Authors:  Jing Yang;  Ji Yang;  HU YUANJIA
Adobe PDF | Favorite | TC[WOS]:2 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/01/02
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors  
Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10 Journal article
Huang, Mu Yang, Chen, Yu Chi, Lyu, Wen Yu, He, Xin Yu, Ye, Zi Han, Huang, Can Yu, He, Xin Ling, Chen, Xiuping, Chen, Xiaobing, Zhang, Baoxian, Kai, Guoyin, Zhang, Xiaolei, Li, Ting, Huang, Mingqing, Lu, Jin Jian. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10[J]. Pharmacological Research, 2023, 198, 106988.
Authors:  Huang, Mu Yang;  Chen, Yu Chi;  Lyu, Wen Yu;  He, Xin Yu;  Ye, Zi Han; et al.
Favorite | TC[WOS]:11 TC[Scopus]:14  IF:9.1/9.0 | Submit date：2024/01/02
Combination Treatment  Ginsenoside Rh2  Pd-1/pd-l1  t Cells  Tumor Microenvironment  
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov Journal article
Yang, Jing, Kang, Heming, Lyu, Liyang, Xiong, Wei, Hu, Yuanjia. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov[J]. Discover Oncology, 2023, 14(1), 151.
Authors:  Yang, Jing;  Kang, Heming;  Lyu, Liyang;  Xiong, Wei;  Hu, Yuanjia
Favorite | TC[WOS]:7 TC[Scopus]:7 | Submit date：2023/09/21
Bispecific Antibodies  Combination Therapy  Immuno-oncology Therapy  Kinase Inhibitors  Pd-1/pd-l1 Inhibitors  Targeted Therapy  
A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance Journal article
Li, Wenxi, Yan, Jie, Tian, Hao, Li, Bei, Wang, Guohao, Sang, Wei, Zhang, Zhan, Zhang, Xuanjun, Dai, Yunlu. A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance[J]. Bioactive Materials, 2023, 22, 34-46.
Authors:  Li, Wenxi;  Yan, Jie;  Tian, Hao;  Li, Bei;  Wang, Guohao; et al.
Favorite | TC[WOS]:20 TC[Scopus]:20  IF:18.0/18.2 | Submit date：2023/05/02
Anti-angiogenesis  Anti-tumorigenesis  Melanoma Pd-1:Pd-l1 Interaction Blockade  Platinum@polymer-catechol Nanobrakers  Radio-sensitization Effect